Haemophilus b conjugate vaccine (meningococcal protein conjugate) - Biologic Drug Details

Summary for haemophilus b conjugate vaccine (meningococcal protein conjugate)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for haemophilus b conjugate vaccine (meningococcal protein conjugate)

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Haemophilus Influenzae B Vaccine
Chemical Structure	Haemophilus Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for haemophilus b conjugate vaccine (meningococcal protein conjugate) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for haemophilus b conjugate vaccine (meningococcal protein conjugate) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for haemophilus b conjugate vaccine (meningococcal protein conjugate) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)

Introduction

The Haemophilus b conjugate vaccine is a crucial biologic drug designed to protect against Haemophilus influenzae type b (Hib), a bacterium that can cause severe and life-threatening illnesses such as meningitis, epiglottitis, and pneumonia. Here, we delve into the market dynamics and financial trajectory of this vaccine, highlighting key drivers, market size, and future projections.

Market Size and Growth

The global conjugate vaccine market, which includes the Haemophilus b conjugate vaccine, was estimated to be valued at USD 19.01 billion in 2023. This market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9.60% from 2024 to 2030[1][5].

Key Drivers of Growth

Several factors are driving the growth of the Haemophilus b conjugate vaccine market:

Rising Incidence of Infectious Diseases

The increasing incidence of infectious diseases globally is a significant driver. Haemophilus b conjugate vaccines help protect against serious bacterial diseases, including Hib, pneumococcal infections, and meningococcal infections[1].

Enhanced Immune Response

Conjugate vaccines, like the Haemophilus b conjugate vaccine, enhance antibody avidity, herd immunity, immunologic memory, and antibody persistence. These benefits make them highly effective in controlling diseases such as Hib and pneumococcal infections[1].

Government-Led Immunization Campaigns

Government initiatives and immunization campaigns, particularly in regions like Asia Pacific, are boosting the demand for conjugate vaccines. Countries such as China and India are witnessing a surge in vaccine demand due to rising awareness about infectious diseases[1].

Market Segmentation

Product Type

The monovalent conjugate vaccine segment, which includes the Haemophilus b conjugate vaccine, dominated the market with a share of 57.92% in 2023. These vaccines are preferred for immunizing against specific infectious diseases and have proven effective in controlling diseases like Hib and pneumococcal infections[1].

Geographic Region

The Asia Pacific region is anticipated to witness the fastest growth, with a CAGR of 25.13% over the forecast period. This growth is driven by rapid urbanization, growing population density, and increasing healthcare expenditure in countries like China and India[1].

Financial Trajectory

Current Market Value

The global conjugate vaccine market, including the Haemophilus b conjugate vaccine, was valued at USD 18,012.08 million in 2022. This market is expected to exhibit a CAGR of 9.6% from 2022 to 2030[5].

Future Projections

By 2030, the global conjugate vaccine market is projected to grow significantly, driven by increasing demand for effective vaccination strategies against bacterial infections. The rising prevalence of bacterial infections, especially in the Middle East and Africa, and the development of expanded-valency pneumococcal conjugate vaccines, are critical drivers of this growth[1][5].

Key Players and Collaborations

Several key players are operating in the conjugate vaccine market, including Merck & Co., Inc., Pfizer, Inc., Sanofi, and Serum Institute of India Pvt. Ltd. These companies are engaged in various collaborations and partnerships to develop and introduce new vaccines. For instance, the partnership between Merck and Sanofi Pasteur led to the development of VAXELIS, a hexavalent combination vaccine that includes the Haemophilus b conjugate vaccine[5].

Regulatory Approvals

Regulatory approvals play a crucial role in the growth of the conjugate vaccine market. For example, the U.S. FDA approved MenQuadfi Meningococcal Conjugate Vaccine in April 2020, which uses tetanus toxoid as a protein carrier. Such approvals enhance market confidence and drive growth[5].

Restraints and Challenges

Despite the growth potential, the conjugate vaccine market faces certain restraints. These include high development costs, stringent regulatory requirements, and the need for continuous research and development to address emerging bacterial strains[5].

Impact of COVID-19

The COVID-19 pandemic has had a positive impact on the conjugate vaccine market. Increased vaccine approvals from regulatory bodies like the U.S. FDA during the pandemic have boosted growth. The pandemic has also highlighted the importance of vaccination strategies, further driving demand for conjugate vaccines[5].

Herd Immunity and Long-Term Protection

Conjugate vaccines like the Haemophilus b conjugate vaccine promote herd immunity and provide long-lasting protection. This is particularly significant for meningococcal conjugate vaccines, which are expected to hold a substantial market share due to their ability to create herd immunity and offer long-term protection[3].

"Meningococcal Conjugate Vaccine Promotes Herd Immunity" - The meningococcal conjugate vaccine (MCV4) segment is expected to hold a 41.6% market share in 2024, driven by its ability to create herd immunity and provide long-lasting protection[3].

Conclusion

The Haemophilus b conjugate vaccine is a vital component of the global conjugate vaccine market, driven by the rising incidence of infectious diseases, enhanced immune response, and government-led immunization campaigns. With a projected CAGR of 9.6% from 2022 to 2030, the market is poised for significant growth. Key players and regulatory approvals are further driving this growth, despite some restraints.

Key Takeaways

• The global conjugate vaccine market, including the Haemophilus b conjugate vaccine, is expected to grow at a CAGR of 9.6% from 2022 to 2030.
• The monovalent conjugate vaccine segment dominates the market.
• Asia Pacific is the fastest-growing region due to rapid urbanization and increasing healthcare expenditure.
• Regulatory approvals and collaborations among key players are driving market growth.
• The COVID-19 pandemic has highlighted the importance of vaccination strategies, boosting demand for conjugate vaccines.

FAQs

1. What is the primary use of the Haemophilus b conjugate vaccine? The Haemophilus b conjugate vaccine is used to prevent infections caused by the Haemophilus influenzae type b (Hib) bacteria, which can lead to life-threatening illnesses such as meningitis and pneumonia[2].

2. Which segment dominates the conjugate vaccine market? The monovalent conjugate vaccine segment, which includes the Haemophilus b conjugate vaccine, dominates the market with a share of 57.92% in 2023[1].

3. What is the expected CAGR of the global conjugate vaccine market from 2022 to 2030? The global conjugate vaccine market is expected to exhibit a CAGR of 9.6% from 2022 to 2030[5].

4. Which region is anticipated to witness the fastest growth in the conjugate vaccine market? The Asia Pacific region is anticipated to witness the fastest growth, with a CAGR of 25.13% over the forecast period[1].

5. How do conjugate vaccines like the Haemophilus b conjugate vaccine enhance immune response? Conjugate vaccines enhance antibody avidity, herd immunity, immunologic memory, and antibody persistence, making them highly effective in controlling bacterial diseases[1].

Sources

1. Grand View Research - Conjugate Vaccine Market Size, Share, Growth Report, 2030
2. Mayo Clinic - Haemophilus b conjugate vaccine (intramuscular route)
3. Fact.MR - Meningococcal Vaccine Market size and Growth Analysis | 2034
4. Taylor & Francis Online - Ambiguous Capture: Collaborative Capitalism and the Meningitis ...
5. Coherent Market Insights - Conjugate Vaccine Market Size, Trends and Forecast to 2030